Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

NHLBI TOPMed - Centers for Common Disease Genomics (CCDG): The BioMe Biobank at Mount Sinai

ABSTRACT: NHLBI TOPMed - Centers for Common Disease Genomics (CCDG): The BioMe Biobank at Mount Sinai

PROVIDER: PRJNA478091 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
		Other

Items per page:

1 - 1 of 1

Similar Datasets

NHLBI TOPMed - Centers for Common Disease Genomics (CCDG): The BioMe Biobank at Mount Sinai

Project description:NHLBI TOPMed - Centers for Common Disease Genomics (CCDG): The BioMe Biobank at Mount Sinai

| PRJNA478092 | ENA

A functional genomics predictive network model identifies regulators of inflammatory bowel disease: Mount Sinai Hospital (MSH) Population Specimen Collection and Profiling of Inflammatory Bowel Disease

Project description:This study focuses on inflammatory bowel disease gene expression profiling. Surgical specimens from 134 patients undergoing bowel resection for inflammatory bowel disease (IBD) and non IBD controls at Mount Sinai Medical Center were collected as the source of tissue. Control samples (CLs) were harvested from normal non inflamed bowel located more than 10 cm away from the tumor from patients undergoing bowel resection for sporadic colon cancer. Ulcerative colitis (UC) and Crohn’s (CD) patient samples were all isolated from areas containing moderate to severe inflammation. The diagnostic pathology report for each specimen was provided by the Mount Sinai Hospital Pathology Department. Patients with UC and patients with CD shared common medications including corticosteroids, infliximab, azathioprine, and mesalamine.

2017-07-07 | GSE83687 | GEO

PAGE: IPM BioMe Biobank

Project description:The Institute for Personalized Medicine (IPM) BioMe Biobank is a consented, EMR-linked medical care setting biorepository of the Mount Sinai Medical Center (MSMC) drawing from a population of over 70,000 inpatients and 800,000 outpatient visits annually. MSMC serves diverse local communities of upper Manhattan, including Central Harlem (86% African American), East Harlem (88% Hispanic Latino), and Upper East Side (88% Caucasian/white) with broad health disparities. IPM BioMe Biobank populations include 28% African American, 38% Hispanic Latino predominantly of Caribbean origin, 23% Caucasian/White. IPM BioMe Biobank disease burden is reflective of health disparities with broad public health impact. Biobank operations are fully integrated in clinical care processes, including direct recruitment from clinical sites waiting areas and phlebotomy stations by dedicated Biobank recruiters independent of clinical care providers, prior to or following a clinician standard of care visit. Recruitment currently occurs at a broad spectrum of over 30 clinical care sites. This study is part of the Population Architecture using Genomics and Epidemiology (PAGE) study (<a href="http://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs000356.v1.p1">phs000356</a>).

| phs000925 | dbGaP

BioMe Biobank Program T2D-GENES Exome Sequencing Study

Project description:BioMe Biobank Program T2D-GENES Exome Sequencing Study

| PRJNA420610 | ENA

BioMe Biobank Program T2D-GENES Exome Sequencing Study

Project description:BioMe Biobank Program T2D-GENES Exome Sequencing Study

| PRJNA427042 | ENA

PAGE: The Charles Bronfman Institute for Personalized Medicine (IPM) BioMe Biobank

Project description:PAGE: The Charles Bronfman Institute for Personalized Medicine (IPM) BioMe Biobank

| PRJNA285518 | ENA

ELDER-BIOME

Project description:ELDER-BIOME

| PRJEB42265 | ENA

Lake Sinai virus

Project description:Lake Sinai virus Targeted Locus (Loci)

| PRJNA608977 | ENA

Common and rare variant prediction and penetrance of IBD in a large, multi-ethnic, health system-based biobank cohort

Project description:Background and aims: As genome sequencing technologies rapidly expand in capacity and availability, understanding how genetic background in different populations modifies IBD risk will be an important factor in disease prediction, prevention, and treatment. However, most of the datasets that are used to generate polygenic risk scores (PRS) contain predominantly European ancestry patients. To address this, we tested different models for prediction of IBD cases using PRS built using association data from multiple races and also assessed the penetrance of rare very early onset IBD (VEOIBD) SNPs. Methods: PRS were calculated using association data from European, African American, and Ashkenazi Jewish (AJ) studies, as well as a meta-GWAS run using all three association datasets. PRS were then combined using regression modelling to assess which combination of scores was best able to predict IBD status in European, AJ, Hispanic, and African American BioMe Biobank populations. Additionally, rare variants were assessed in genes associated with very early onset IBD, taking into account genetic penetrance in each BioMe population, deleteriousness, and evolutionary conservation. Results: Combining risk scores based on IBD association results from multiple racial populations resulted in improved IBD prediction for every population in BioMe. We also identified highly penetrant rare variants in previously established VEOIBD genes which were predicted to be deleterious, including SNPs in established risk genes such as NOD2 as well as novel variants, including some in LRBA which appear to be particularly relevant for risk of IBD in African Americans.

2021-04-07 | GSE150516 | GEO

gill biome

Project description:gill biome Metagenome

| PRJNA953821 | ENA